Trulicity’s performance was a big positive for Lilly however, as there had been speculation that it might start to slow down thanks to the challenge from Ozempic – which has outperformed it in ...

This week was loaded with earnings releases of many large drugmakers. Novo Nordisk NVO, Merck MRK, Pfizer PFE, Eli Lilly LLY, ...

Higher volumes of drugs like Mounjaro, Zepbound, Verzenio, Jardiance and Taltz were partially offset by lower sales of Trulicity. Lilly’s new products also contributed to sales growth.

2 Lilly defines Growth Products as select products launched prior to 2022, which currently consist of Cyramza, Emgality, Jardiance, Olumiant, Retevmo, Taltz, Trulicity, Tyvyt and Verzenio.

Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology. Having examined the ...

Growth Products revenue increased 13% to $5.95 billion, driven by growth in Verzenio and Jardiance, partially offset by lower Trulicity sales. Also Read: FDA Approves Expanded Use Of Eli Lilly’s ...

Eli Lilly And Co (NYSE:LLY ... Zepbound sales reached $1.26 billion. Trulicity sales fell 22% to $1.30 billion. GLP-1 diabetes sales increased by 12%, and Obesity care sales increased by 91% ...

Trulicity’s performance was a big positive for Lilly however, as there had been speculation that it might start to slow down thanks to the challenge from Ozempic – which has outperformed it in ...